CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤的新型免疫疗法——机遇与挑战
英文原题：Novel immunotherapies in multiple myeloma - chances and challenges.
查看英文原题
Novel immunotherapies in multiple myeloma - chances and challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在这篇综述文章中，我们总结了抗体-药物偶联物、双特异性T细胞衔接抗体和CAR-T 细胞治疗多发性骨髓瘤的最新数据。我们讨论了这些新型免疫疗法成为多发性骨髓瘤管理标准药物时需要解决的关键问题。我们还关注这些疗法的患者选择，并推测如何最佳地个体化治疗方法。我们认为这些新型免疫疗法代表了范式转变。然而，尽管初步数据令人鼓舞，但许多未解决的问题仍有待未来试验评估。
展开英文摘要原文
In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma.
We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma.
We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches.
We see these novel immunotherapies as representing a paradigm shift.
However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.
论文信息
- 作者
- Rasche L、Wäsch R、Munder M、Goldschmidt H、Raab MS
- 第一作者单位
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg; Mildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg.Germany
- 通讯作者单位
- Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Marc.Raab@med.uni-heidelberg.de.Germany
- 文献类型
- 综述
- 期刊
- Haematologica2021 Oct 1
- 原文标识
- PubMed 34196164 · DOI 10.3324/haematol.2020.266858
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →